252 related articles for article (PubMed ID: 24479685)
1. Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages.
Kuss M; Adamopoulou E; Kahle PJ
J Neurochem; 2014 Jun; 129(6):980-7. PubMed ID: 24479685
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
Gillardon F; Schmid R; Draheim H
Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
[TBL] [Abstract][Full Text] [Related]
3. LRRK2: dropping (kinase) inhibitions and seeking an (immune) response.
Mamais A; Cookson MR
J Neurochem; 2014 Jun; 129(6):895-7. PubMed ID: 24661004
[No Abstract] [Full Text] [Related]
4. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
Deng X; Elkins JM; Zhang J; Yang Q; Erazo T; Gomez N; Choi HG; Wang J; Dzamko N; Lee JD; Sim T; Kim N; Alessi DR; Lizcano JM; Knapp S; Gray NS
Eur J Med Chem; 2013; 70():758-67. PubMed ID: 24239623
[TBL] [Abstract][Full Text] [Related]
5. Crohn's and Parkinson's Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14
Ikezu T; Koro L; Wolozin B; Farraye FA; Strongosky AJ; Wszolek ZK
J Neuroimmune Pharmacol; 2020 Dec; 15(4):794-800. PubMed ID: 32180132
[TBL] [Abstract][Full Text] [Related]
6. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
Luerman GC; Nguyen C; Samaroo H; Loos P; Xi H; Hurtado-Lorenzo A; Needle E; Stephen Noell G; Galatsis P; Dunlop J; Geoghegan KF; Hirst WD
J Neurochem; 2014 Feb; 128(4):561-76. PubMed ID: 24117733
[TBL] [Abstract][Full Text] [Related]
7. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.
Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR
PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to
Weindel CG; Bell SL; Vail KJ; West KO; Patrick KL; Watson RO
Elife; 2020 Feb; 9():. PubMed ID: 32057291
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
[TBL] [Abstract][Full Text] [Related]
10. Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells.
Panagiotakopoulou V; Ivanyuk D; De Cicco S; Haq W; Arsić A; Yu C; Messelodi D; Oldrati M; Schöndorf DC; Perez MJ; Cassatella RP; Jakobi M; Schneiderhan-Marra N; Gasser T; Nikić-Spiegel I; Deleidi M
Nat Commun; 2020 Oct; 11(1):5163. PubMed ID: 33057020
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
12. Leucine-rich repeat kinase 2-sensitive Na+/Ca2+ exchanger activity in dendritic cells.
Yan J; Almilaji A; Schmid E; Elvira B; Shimshek DR; van der Putten H; Wagner CA; Shumilina E; Lang F
FASEB J; 2015 May; 29(5):1701-10. PubMed ID: 25609428
[TBL] [Abstract][Full Text] [Related]
13. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β.
Kawakami F; Shimada N; Ohta E; Kagiya G; Kawashima R; Maekawa T; Maruyama H; Ichikawa T
FEBS J; 2014 Jan; 281(1):3-13. PubMed ID: 24165324
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
15. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
Daniëls V; Baekelandt V; Taymans JM
Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
[TBL] [Abstract][Full Text] [Related]
16. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 is involved in the IFN-gamma response and host response to pathogens.
Gardet A; Benita Y; Li C; Sands BE; Ballester I; Stevens C; Korzenik JR; Rioux JD; Daly MJ; Xavier RJ; Podolsky DK
J Immunol; 2010 Nov; 185(9):5577-85. PubMed ID: 20921534
[TBL] [Abstract][Full Text] [Related]
18. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.
Sarközi R; Miller B; Pollack V; Feifel E; Mayer G; Sorokin A; Schramek H
J Cell Physiol; 2007 Apr; 211(1):88-100. PubMed ID: 17131384
[TBL] [Abstract][Full Text] [Related]
19. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein.
Niu J; Yu M; Wang C; Xu Z
J Neurochem; 2012 Aug; 122(3):650-8. PubMed ID: 22639965
[TBL] [Abstract][Full Text] [Related]
20. The Parkinson's disease-associated kinase LRRK2 regulates genes required for cell adhesion, polarization, and chemotaxis in activated murine macrophages.
Levy DR; Udgata A; Tourlomousis P; Symmons MF; Hopkins LJ; Bryant CE; Gay NJ
J Biol Chem; 2020 Jul; 295(31):10857-10867. PubMed ID: 32111741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
